Matrix metalloproteinases -8 and -9 in the Airways, Blood and Urine During Exacerbations of COPD

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012; 380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Silva MT. When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol 2010; 87(1):93–106.
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: Comparisons with asthma. J Allergy Clin Immunol 2003; 112(5):819–827.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD Exacerbations: Defining their cause and prevention. Lancet 2007; 370(9589):786–796.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Mercer PF, Shute JK, Bhowmik A, et al. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005; 6:151.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97(6):634–639.
   PubMed Web of Science ®Google Scholar
• Boschetto P, Quintavalle S, Zeni E, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006; 61(12):1037–1042.
   PubMed Web of Science ®Google Scholar
• Ilumets H, Rytila PH, Sovijarvi AR, et al. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scand J Clin Lab Invest 2008; 68(7):618–623.
   PubMed Web of Science ®Google Scholar
• Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004; 37(6):768–784.
   PubMed Web of Science ®Google Scholar
• Kinnula VL. Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax 2005; 60(8):693–700.
   PubMed Web of Science ®Google Scholar
• Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28(1):219–242.
   PubMed Web of Science ®Google Scholar
• Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19(1):34–41.
   PubMed Web of Science ®Google Scholar
• Ilumets H, Rytila P, Demedts I, et al. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis 2007; 2(3):369–379.
   PubMedGoogle Scholar
• Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56(4):515–548.
   PubMed Web of Science ®Google Scholar
• Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 2002; 30(2):98–102.
   PubMed Web of Science ®Google Scholar
• Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(6):1304–1309.
   PubMed Web of Science ®Google Scholar
• Haq I, Chappell S, Johnson SR, et al. Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 2010; 11:7.
   PubMed Web of Science ®Google Scholar
• Glasgow CG, Steagall WK, Taveira-Dasilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 2010; 104 Suppl 1:S45–58.
   PubMed Web of Science ®Google Scholar
• Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58(7):1395–1399.
   PubMed Web of Science ®Google Scholar
• Higashimoto Y, Iwata T, Okada M, et al. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009; 103(8):1231–1238.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre, 2010. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English.. (Accessed February 1, 2015).
   Google Scholar
• Jones P, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD assessment test. Euro Respir J 2009; 34(3):648–654.
   PubMed Web of Science ®Google Scholar
• Fletcher C. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). Br Med J 1960; 2:1665.
   PubMedGoogle Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26(2):319–338.
   PubMed Web of Science ®Google Scholar
• GOLD. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Available from: http://www.goldcopd.org/. (Accessed February 1, 2015).
   Google Scholar
• Lowrey GE, Henderson N, Blakey JD, et al. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med 2008; 102(6):845–851.
   PubMed Web of Science ®Google Scholar
• Chang W, Cane JL, Blakey J, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res 2012; 13(1):34.
   PubMed Web of Science ®Google Scholar
• Chang WY, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014; 43(4):1114–1123.
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012; 67(7):606–612.
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7(5):e37483.
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92(8):827–839.
   PubMed Web of Science ®Google Scholar
• Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274(19):13066–13076.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2(3):161–174.
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185(10):1065–1072.
   PubMed Web of Science ®Google Scholar
• Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014; 69(7):666–672.
   PubMed Web of Science ®Google Scholar
• Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26(5):602–609.
   PubMed Web of Science ®Google Scholar
• Segura-Valdez L, Pardo A, Gaxiola M, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117(3):684–694.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Dejonckheere E, Libert C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur Respir J 2011; 38(5):1200–1214.
   PubMed Web of Science ®Google Scholar
• Zucker S, Lysik RM, Malik M, et al. Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis. Int J Cancer 1992; 52(3):366–371.
   PubMed Web of Science ®Google Scholar
• Craig VJ, Quintero PA, Fyfe SE, et al. Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J Immunol 2013; 190(8):4283–4296.
   PubMed Web of Science ®Google Scholar
• Smith ER, Zurakowski D, Saad A, et al. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008; 14(8):2378–2386.
   PubMed Web of Science ®Google Scholar
• Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003; 285(1):F9–18.
   PubMed Web of Science ®Google Scholar
• Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol 2003; 171(12):6630–6639.
   PubMed Web of Science ®Google Scholar
• Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276(40):37258–37265.
   PubMed Web of Science ®Google Scholar